127 related articles for article (PubMed ID: 15520762)
1. Clinical and cost implications of target joints in Canadian boys with severe hemophilia A.
Kern M; Blanchette V; Stain AM; Einarson TR; Feldman BM
J Pediatr; 2004 Nov; 145(5):628-34. PubMed ID: 15520762
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
3. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
4. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic use of factor VIII: an economic evaluation.
Bohn RL; Avorn J; Glynn RJ; Choodnovskiy I; Haschemeyer R; Aledort LM
Thromb Haemost; 1998 May; 79(5):932-7. PubMed ID: 9609224
[TBL] [Abstract][Full Text] [Related]
6. Utilization and costs for children who have special health care needs and are enrolled in a hospital-based comprehensive primary care clinic.
Berman S; Rannie M; Moore L; Elias E; Dryer LJ; Jones MD
Pediatrics; 2005 Jun; 115(6):e637-42. PubMed ID: 15930189
[TBL] [Abstract][Full Text] [Related]
7. [Hemophilic arthropathies. Apropos of 51 cases].
Minckes O; Rialland X; Laumonnier F; Fressinaud E; Atanasiu JP; Larget-Piet L
Ann Pediatr (Paris); 1989 Sep; 36(7):425-34. PubMed ID: 2817697
[TBL] [Abstract][Full Text] [Related]
8. Cost of severe haemophilia in Toronto.
Heemstra HE; Zwaan T; Hemels M; Feldman BM; Blanchette V; Kern M; Einarson TR
Haemophilia; 2005 May; 11(3):254-60. PubMed ID: 15876271
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran.
Daliri AA; Haghparast H; Mamikhani J
Int J Technol Assess Health Care; 2009 Oct; 25(4):584-7. PubMed ID: 19845990
[TBL] [Abstract][Full Text] [Related]
10. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan.
Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM
Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742
[TBL] [Abstract][Full Text] [Related]
11. Association between joint bleeds and Pettersson scores in severe haemophilia.
Fischer K; van Hout BA; van der Bom JG; Grobbee DE; van den Berg HM
Acta Radiol; 2002 Sep; 43(5):528-32. PubMed ID: 12423465
[TBL] [Abstract][Full Text] [Related]
12. Joint Aspiration for Acute Hemarthrosis in Children Receiving Factor VIII Prophylaxis for Severe Hemophilia: 11-year Safety Data.
Manners PJ; Price P; Buurman D; Lewin B; Smith B; Cole CH
J Rheumatol; 2015 May; 42(5):885-90. PubMed ID: 25729030
[TBL] [Abstract][Full Text] [Related]
13. An approach to target joint bleeding in hemophilia: prophylaxis for all or individualized treatment?
Abshire T
J Pediatr; 2004 Nov; 145(5):581-3. PubMed ID: 15520752
[No Abstract] [Full Text] [Related]
14. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed.
van Dijk K; Fischer K; van der Bom JG; Grobbee DE; van den Berg HM
Haemophilia; 2005 Sep; 11(5):438-43. PubMed ID: 16128885
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis in people with haemophilia.
Coppola A; Franchini M; Tagliaferri A
Thromb Haemost; 2009 Apr; 101(4):674-81. PubMed ID: 19350110
[TBL] [Abstract][Full Text] [Related]
16. Intraarticular bleeding in children with hemophilia: the prevention of arthropathy.
Gregosiewicz A; Wośko I; Kandzierski G
J Pediatr Orthop; 1989; 9(2):182-5. PubMed ID: 2494223
[TBL] [Abstract][Full Text] [Related]
17. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.
Tagliaferri A; Franchini M; Coppola A; Rivolta GF; Santoro C; Rossetti G; Feola G; Zanon E; Dragani A; Iannaccaro P; Radossi P; Mannucci PM
Haemophilia; 2008 Sep; 14(5):945-51. PubMed ID: 18540895
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
Fischer K; Valentino L; Ljung R; Blanchette V
Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
[TBL] [Abstract][Full Text] [Related]
19. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
Mahasandana C; Patharathienskul D; Suvatte V
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
[TBL] [Abstract][Full Text] [Related]
20. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
